MBRX Moleculin Biotech, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1659617 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY79.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-55.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets30.1%
Debt / equity0.00x
Current ratio1.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.37x
Accruals ratio76.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $4.49M | $5.45M | $5.38M | $5.12M | $3.74M | $3.60M | $3.44M | $4.46M |
| SG&A expense | $2.11M | $2.10M | $2.49M | $2.41M | $2.15M | $2.09M | $2.48M | $2.16M |
| Operating income | -$6.61M | -$7.56M | -$7.87M | -$7.53M | -$5.91M | -$5.72M | -$5.94M | -$6.64M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.49M | -$7.63M | -$12.85M | $15.55M | -$25.40M | -$17.81M | -$5.90M | -$6.58M |
| EBITDA | -$6.60M | -$7.55M | -$7.87M | -$7.52M | -$5.88M | -$5.69M | -$5.91M | -$6.61M |
| EPS (basic) | -9.59 | -1.40 | -3.54 | — | -340.43 | -28.68 | -15.80 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.29M | $7.26M | $10.32M | $8.88M | $6.70M | $7.56M | $7.72M | $4.28M |
| Current assets | $8.41M | $8.72M | $10.96M | $9.69M | $7.88M | $9.08M | $9.34M | $5.19M |
| PP&E, net | $54,000 | $62,000 | $70,000 | $78,000 | $77,000 | $99,000 | $127,000 | $159,000 |
| Total assets | $20.74M | $21.09M | $23.36M | $22.13M | $20.35M | $21.59M | $21.01M | $16.93M |
| Current liabilities | $6.13M | $9.31M | $7.96M | $6.85M | $5.68M | $7.91M | $6.90M | $5.36M |
| Total liabilities | $6.25M | $9.50M | $8.18M | $7.12M | $47.27M | $25.18M | $7.22M | $5.72M |
| Shareholders' equity | $14.49M | $11.59M | $15.18M | $15.01M | -$26.92M | -$3.58M | $13.79M | $11.21M |
| Shares outstanding | 1.05M | 7.10M | 5.34M | 159,961 | 49.50M | 30.21M | 14.13M | 135,155 |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.97M | -$6.66M | -$6.11M | -$5.37M | -$7.22M | -$5.58M | -$4.56M | -$5.08M |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | — | — | — | -$5.37M | -$7.22M | -$5.58M | -$4.56M | -$5.08M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $9.03M | $3.61M | $7.61M | $7.49M | $6.38M | $5.42M | $8.00M | $1,000 |
| Depreciation & amortization | $8,000 | $8,000 | $8,000 | $9,000 | $21,000 | $29,000 | $31,000 | $31,000 |
| Stock-based compensation | $393,000 | $436,000 | $380,000 | $459,000 | $303,000 | $417,000 | $485,000 | $427,000 |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.